154 related articles for article (PubMed ID: 25232966)
61. Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria.
Elisi GM; Bedini A; Scalvini L; Carmi C; Bartolucci S; Lucini V; Scaglione F; Mor M; Rivara S; Spadoni G
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899888
[No Abstract] [Full Text] [Related]
62. Quantum mechanics insights into melatonin and analogs binding to melatonin MT
de Lima Menezes G; Sales Bezerra K; Nobre Oliveira JI; Fontenele Araújo J; Soares Galvão D; Alves da Silva R; Vogel Saivish M; Laino Fulco U
Sci Rep; 2024 May; 14(1):10922. PubMed ID: 38740789
[TBL] [Abstract][Full Text] [Related]
63. Structural basis of ligand recognition at the human MT
Stauch B; Johansson LC; McCorvy JD; Patel N; Han GW; Huang XP; Gati C; Batyuk A; Slocum ST; Ishchenko A; Brehm W; White TA; Michaelian N; Madsen C; Zhu L; Grant TD; Grandner JM; Shiriaeva A; Olsen RHJ; Tribo AR; Yous S; Stevens RC; Weierstall U; Katritch V; Roth BL; Liu W; Cherezov V
Nature; 2019 May; 569(7755):284-288. PubMed ID: 31019306
[TBL] [Abstract][Full Text] [Related]
64. 7-Substituted-melatonin and 7-substituted-1-methylmelatonin analogues: effect of substituents on potency and binding affinity.
Faust R; Garratt PJ; Trujillo Pérez MA; Piccio VJ; Madsen C; Stenstrøm A; Frølund B; Davidson K; Teh MT; Sugden D
Bioorg Med Chem; 2007 Jul; 15(13):4543-51. PubMed ID: 17459711
[TBL] [Abstract][Full Text] [Related]
65. N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist.
Sun LQ; Takaki K; Chen J; Iben L; Knipe JO; Pajor L; Mahle CD; Ryan E; Xu C
Bioorg Med Chem Lett; 2004 Oct; 14(20):5157-60. PubMed ID: 15380218
[TBL] [Abstract][Full Text] [Related]
66. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement.
Pala D; Beuming T; Sherman W; Lodola A; Rivara S; Mor M
J Chem Inf Model; 2013 Apr; 53(4):821-35. PubMed ID: 23541165
[TBL] [Abstract][Full Text] [Related]
67. Melatonin in cardiovascular disease.
Dominguez-Rodriguez A
Expert Opin Investig Drugs; 2012 Nov; 21(11):1593-6. PubMed ID: 22916801
[TBL] [Abstract][Full Text] [Related]
68. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
Kamal M; Gbahou F; Guillaume JL; Daulat AM; Benleulmi-Chaachoua A; Luka M; Chen P; Kalbasi Anaraki D; Baroncini M; Mannoury la Cour C; Millan MJ; Prevot V; Delagrange P; Jockers R
J Biol Chem; 2015 May; 290(18):11537-46. PubMed ID: 25770211
[TBL] [Abstract][Full Text] [Related]
69. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.
Mésangeau C; Fraise M; Delagrange P; Caignard DH; Boutin JA; Berthelot P; Yous S
Eur J Med Chem; 2011 May; 46(5):1835-40. PubMed ID: 21392858
[TBL] [Abstract][Full Text] [Related]
70. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
[TBL] [Abstract][Full Text] [Related]
71. Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey.
Bedini A; Boutin JA; Legros C; Zlotos DP; Spadoni G
J Pineal Res; 2024 May; 76(4):e12953. PubMed ID: 38682544
[TBL] [Abstract][Full Text] [Related]
72. Melatonin receptor ligands: A pharmaco-chemical perspective.
Boutin JA; Witt-Enderby PA; Sotriffer C; Zlotos DP
J Pineal Res; 2020 Oct; 69(3):e12672. PubMed ID: 32531076
[TBL] [Abstract][Full Text] [Related]
73. Pharmacological characterization of M-II, the major human metabolite of ramelteon.
Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K
Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230
[TBL] [Abstract][Full Text] [Related]
74. Design, synthesis and melatoninergic potency of new N-acyl 8,9-dihydro-4-methoxy-7H-2-benzo[de]quinolinalkanamines.
Tsotinis A; Eleutheriades A; Hough KA; Davidson K; Sugden D
Bioorg Chem; 2007 Apr; 35(2):189-204. PubMed ID: 17223160
[TBL] [Abstract][Full Text] [Related]
75. A molecular and chemical perspective in defining melatonin receptor subtype selectivity.
Chan KH; Wong YH
Int J Mol Sci; 2013 Sep; 14(9):18385-406. PubMed ID: 24018885
[TBL] [Abstract][Full Text] [Related]
76. Therapeutic potential of melatonin ligands.
Delagrange P; Boutin JA
Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
[TBL] [Abstract][Full Text] [Related]
77. N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability.
Ferlenghi F; Mari M; Gobbi G; Elisi GM; Mor M; Rivara S; Vacondio F; Bartolucci S; Bedini A; Fanini F; Spadoni G
ChemMedChem; 2021 Oct; 16(19):3071-3082. PubMed ID: 34213063
[TBL] [Abstract][Full Text] [Related]
78. Human amniotic epithelial cells express melatonin receptor MT1, but not melatonin receptor MT2: a new perspective to neuroprotection.
Kaneko Y; Hayashi T; Yu S; Tajiri N; Bae EC; Solomita MA; Chheda SH; Weinbren NL; Parolini O; Borlongan CV
J Pineal Res; 2011 Apr; 50(3):272-80. PubMed ID: 21269327
[TBL] [Abstract][Full Text] [Related]
79. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
Leclerc V; Ettaoussi M; Rami M; Farce A; Boutin JA; Delagrange P; Caignard DH; Renard P; Berthelot P; Yous S
Eur J Med Chem; 2011 May; 46(5):1622-9. PubMed ID: 21377769
[TBL] [Abstract][Full Text] [Related]
80. Melatonin receptor structures shed new light on melatonin research.
Cecon E; Liu L; Jockers R
J Pineal Res; 2019 Nov; 67(4):e12606. PubMed ID: 31442321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
